MedTrace Logo

Exercise as a Tool to Improve Response to Immunotherapy in Non-small Cell Lung Cancer

NCT07267000 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-05

No results posted yet for this study

Summary

This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell lung cancer. It has widely been accepted that exercise is preventive against certain types of cancer. Individuals following an active lifestyle have a significantly lower risk for several chronic diseases, including cancer, as compared to sedentary ones. However, evidence is still lacking for exercise as part of routine cancer treatment (as it has already been implemented routinely in patients with heart disease, for example). In this study, patients suffering from non-small cell lung cancer undergo either a 12-week training program consisting of moderate-intensity continuous exercise (MICE), or a 12-week program with high-intensity interval exercise. Both groups will be compared to a control group receiving standard exercise recommendations. The response to immunotherapy, measured by the radiologic therapy response, will be the main endpoint. Additionally, blood will be taken from the patients at different timepoints, and blood samples will be tested for immunologic changes. FACS analysis will be used to assess the properties of immune cells and potential changes upon the exercise regimen. Mitochondrial function will be assessed via the Seahorse machine, and mass spectrometry (lipidomics) will be used for the analysis of lipid profile changes.

Conditions

Interventions

BEHAVIORAL

Exercise

1 study arm doing continuous type exercise will be compared to 1 study arm doing high-intensity interval exercise, over the course of 12 weeks, respectively. Both arms will be compared to sedentary control patients.

OTHER

Control

For patients in the control group, general exercise recommendations (e.g. recommendations by the CDC suitable for all adult individuals) will be given, however, no training therapy intervention is done and no home-based walking exercise is required either.

Sponsors & Collaborators

  • University of Graz

    collaborator OTHER

  • Austrian Science Fund (FWF)

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2028-10-01
Completion
2029-05-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07267000 on ClinicalTrials.gov